Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 2/20 | 0.63 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.63 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | HPGDS | O60760 | 4/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795621 | 0.82 | PIP4K2A (0.62) | PIP4K2APIP4K2BPIP4K2CMAPK14HPGDS | |
| SCHEMBL3928614 | 0.82 | PIP4K2A (0.72) | PIP4K2APIP4K2BPIP4K2CMAPK14HPGDS | |
| SCHEMBL4795136 | 0.81 | HPGDS (0.52) | PIP4K2APIP4K2BPIP4K2CMAPK14HPGDS | |
| SCHEMBL4795811 | 0.80 | PIP4K2A (0.60) | PIP4K2APIP4K2BPIP4K2CMAPK14HPGDS | |
| SCHEMBL4795341 | 0.78 | PIP4K2A (0.58) | PIP4K2APIP4K2BPIP4K2CHPGDSIKBKB | |
| SCHEMBL3925497 | 0.78 | PIP4K2A (0.60) | PIP4K2APIP4K2BPIP4K2CHPGDSIKBKB | |
| SCHEMBL4794701 | 0.78 | PIP4K2A (0.57) | PIP4K2APIP4K2BPIP4K2CHPGDSIKBKB | |
| SCHEMBL3930224 | 0.78 | PIP4K2A (0.62) | PIP4K2APIP4K2BPIP4K2CMAPK14HPGDS | |
| SCHEMBL4793932 | 0.78 | PIP4K2A (0.60) | PIP4K2APIP4K2BPIP4K2CHPGDSIKBKB | |
| SCHEMBL4781310 | 0.77 | PIP4K2A (0.59) | PIP4K2APIP4K2BPIP4K2CHPGDSIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | PIP4K2A 4321/4885PIP4K2B 4353/4885PIP4K2C 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.